Inactive Instrument

Endologix, Inc.

Equities

ELGXQ

US29266S3040

Medical Equipment, Supplies & Distribution

ENDOLOGIX INC /DE/ : Other Events (form 8-K)

December 19, 2019 at 06:05 am EST

Item 8.01 Other Events

On December 16, 2019, Endologix Inc. (the "Company") filed its response to the U.S. Food and Drug Administration's June 11, 2019 deficiency letter regarding the Company's Alto® Abdominal Stent Graft System.

--------------------------------------------------------------------------------

Latest news about Endologix, Inc.

Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	Mar. 05	CI
Endologix LLC Announces That Art Taylor Joins Board of Directors	Jan. 25	CI
Endologix LLC Appoints Scott Ward Joins Board of Directors	Jan. 09	CI
Endologix LLC Announces Appointment of Scott Ward as Board of Directors	Jan. 09	CI
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	Dec. 27	CI
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	Nov. 02	CI
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	23-09-07	CI
Endologix LLC Appoints Lucas Buchanan to its Board of Directors	23-08-24	CI
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	23-07-18	CI
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	23-06-15	CI
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	23-06-08	CI
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	23-05-23	CI
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	22-11-11	CI
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	22-11-03	CI
Endologix LLC Announces the Elevate	22-10-20	CI
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System	22-10-10	CI
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting	22-06-23	CI
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA	21-11-23	CI
Endologix Appoints Dr. Matthew Thompson as CEO	21-11-16	CI
Endologix, Inc. Announces Board and Executive Changes	21-11-16	CI
Endologix LLC Initiates Randomized Study of ALTO® Abdominal Stent Graft System	21-09-29	CI
Endologix Llc Receives U.S. Food and Drug Administration Breakthrough Device Designation for ChEVAS System	21-07-19	CI
Endologix Llc Announces Launch of Alto Abdominal Stent Graft System in Canada and Argentina	21-05-11	CI
Endologix, Inc. acquired PQ Bypass, Inc. for approximately $300 million.	21-04-12	CI
TriVascular Sales LLC Emerged from Bankruptcy	20-10-01	CI

Chart Endologix, Inc.

Duration

Period

More charts

Company Profile

Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company's products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company's solution for sealing the aneurysm sac while maintaining blood flow. The Company's EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company's EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Medical Devices & Implants

	1st Jan change	Capi.
STRYKER CORPORATION	+12.70%	127B
SMITH & NEPHEW PLC	-8.82%	10.68B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-2.20%	8.59B
INSPIRE MEDICAL SYSTEMS, INC.	+15.49%	7.09B
GLAUKOS CORPORATION	+29.09%	5.07B
AXONICS, INC.	+7.10%	3.39B
ENOVIS CORPORATION	-0.27%	3.04B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-10.28%	2.02B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-8.61%	2B

Medical Devices & Implants